Published in Hepatitis Weekly, May 6th, 2002
That's what a multicenter team of investigators in France said in a new report of a fibrosis index they developed and evaluated in a retrospective study of more than 150 patients infected with hepatitis C virus (HCV) who had been randomized to receive standard or more aggressive IFN therapy.
"One-hundred sixty-five patients who had had two interpretable liver biopsies and at least one stored serum sample before IFN treatment were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.